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Objectives. This study aims to determine safety, short and mid-term outcomes of Carotid Artery Stenting (CAS) and
Endarterectomy (CEA) during the last 6 years in a single vascular surgery center.
Methods.We retrospectively reviewed 2624 consecutive carotid revascularizations performed between December 2000 and
December 2006 in 2176 patients with severe carotid artery stenosis (symptomatic 70%, asymptomatic 80%), of which
1589 were CEA and 1035 CAS. Patients were followed up at 1, 3, 6 and 12 months after the procedure and then yearly.
Results. The percutaneous procedure was successful in 99.2% of the cases. No intra-procedural death occurred. The overall
death and stroke rates at 30 days, 1 year and 3 years were 1.54%, 2.86%, 7.43% in the CAS group and 2.07%, 3.55%,
6.95% in the CEA group, respectively ( p value not significant in any case).
Conclusions. At our vascular surgery centre the results of CEA and CAS are similar. CAS has become our standard of
care in preventing strokes and is an effective alternative to CEA for low-risk patients as well.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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In Western countries, stroke is the third leading cause
of death and is the most common cause of permanent
disability.1 A stenosis of the internal carotid artery
may be responsible for 10% to 20% of all strokes or
transient ischemic attacks (TIA). Carotid artery stent-
ing (CAS) has emerged as a useful, potentially less-
invasive alternative to carotid endarterectomy (CEA)
but controversy presently surrounds this procedure.2
Part of the controversy arises from confusion regard-
ing which physicians should treat carotid artery
disease. Vascular surgeons, neurosurgeons, interven-
tional cardiologists, neuroradiologists, radiologists,
cardiac or general surgeons have openly embraced
the treatment of carotid disease and in particular
this new technology (CAS). At the same time, during
the last decade there have been important innovations
in the device, technical refinements and a better
knowledge of patient selection. With the introduction
of CAS, vascular surgeons have been challenged to
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artery stenosis. The two most referenced trials in the
current clinical decision-making process for carotid
stenosis are the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) and the Asymptom-
atic Carotid Atherosclerosis Study (ACAS). Both con-
cluded there was a clear benefit to CEA in patients
with symptomatic and asymptomatic carotid occlu-
sive disease.3,4 In current clinical practice, CAS has
emerged as a viable alternative for patients who are
deemed at high risk for surgery or poor candidates
for CEA, which is considered the standard of care.5
Several trials have suggested equivalent results for
CAS and CEA.6e9
The purpose of this report was to review our experi-
encewithCAS in comparing toCEAover the last 6years.
Methods
Between December 2000 and December 2006, 1027
successful CAS procedures (out of 1035 attempted
procedures: procedural success 99.2%) were per-
formed in our center of Vascular and Endovascular
Surgery at the University of Siena, in 937 patients
(98 treated with staged bilateral procedures). Thisn behalf of European Society for Vascular Surgery.
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the same period (CEA 1589 procedures in 1368
patients). Our indications for treatment were the pres-
ence of a symptomatic carotid-artery stenosis 70% or
an asymptomatic stenosis of at least 80%. A large
number of lesions were symptomatic (n¼ 1238,
47.2%).
The demographic data and neurological history of
the two study groups (CAS vs CEA) are summarized
in Table 1. Demographic variables, clinical data, intra-
operative and follow-up data were collected by the
operative team in a special database. Written in-
formed consent for intervention was obtained from
all patients. Carotid stenting was carried out using
self-expandable stents in all cases. Cerebral protection
devices were also used in all cases, involving distal fil-
ter devices (91.1%), occlusive distal balloon (0.9%) or
proximal balloon protection (8%). The majority of pro-
cedures were elective (CAS n¼ 1002; CEA n¼ 1527)
while the remaining were urgent interventions (CAS
n¼ 33; CEA n¼ 62). The reasons for urgent treatment
were the same for both groups: amaurosis fugax, cre-
scendo TIA or acute minor stroke within 14-28 days
from the onset of symptoms (modified Rankin scale
score <3).
Data analysis included minor, major or fatal strokes
and deaths (procedure-related and non-procedure-
Table 1. Demographic data and neurological history of the patient
groups. CAS, carotid artery stenting; CEA, endarterectomy;
COPD, Chronic Obstructive Pulmonary Disease; ASA, Score of
the American Society of Anesthesiologists
CAS CEA p-value
Clinical data No. % No. %
Procedures 1035 100.00 1589 100.00 e
Mean age 74 S.D. 3 65 S.D. 6.4 p< 0.05
Over 80 years 141 13.65 24 1.49 p< 0.001
Hypertension 736 71.11 1164 73.29 p¼ 0.22
Smokers 605 58.5 838 52.75 p¼ 0.004
Diabete mellitus 321 30.98 524 32.98 p¼ 0.30
Coronary artery disease 458 44.22 706 44.45 p¼ 0.93
Hypercolesterolemia 285 27.52 410 25.79 p¼ 0.34
Heart failure 231 22.37 381 23.97 p¼ 0.34
COPD 321 30.98 459 28.90 p¼ 0.25
Peripheral arterial
disease
221 21.32 331 20.86 p¼ 0.76
Post-CEA restenosis 139 13.44 13 0.84 p< 0.001
Post-attinic stenosis 35 3.04 3 0.19 p< 0.001
Previous radical
surgery of the neck




463 44.74 58 3.69 p< 0.001
Carotid post-stenting
restenosis
18 1.74 e e e
Neurological history No. % No. %
Symptomatic lesions 438 42.33 757 47.63 p¼ 0.008
Asymptomatic lesions 596 57.67 832 52.37 p¼ 0.008
Eur J Vasc Endovasc Surg Vol 34, December 2007related), at discharge, at 30 days, at 1 and at 3 years
and MI at 30 days. We also evaluated the overall death
(procedure-related and non-procedure-related) and
stroke rateat30days, 1yearand3years forCASandCEA.
A transient ischemic attack (TIA) was defined as
a focal, retinal or hemispheric event from which the
patient made a complete recovery within 24 hours.
A minor stroke was defined as a new neurological
deficit that either resolved completely within 30
days or increased on the NIH (National Institutes of
Health) Stroke Scale by 3. A major stroke was
defined as a new neurological deficit that persisted
>30 days and increased on the NIH Stroke Scale by
4. A fatal stroke was defined as death attributed to
an ischemic stroke or intra-cerebral hemorrhagic
stroke. MI was defined as new evidence of myocardial
damage as indicated by elevation of either creatine
kinase or CK-MB to more than 2 times the upper limit
of normal and troponin T> 0.1 ng/mL, usually in the
setting of chest pain or electrocardiogram changes.
Table 2 shows baseline ultrasound lesion characteris-
tics (Gray-Weale Classification10) between treatment
arms.
CAS Procedure
Carotid stenting was carried out using self-expanding
stents exclusively. Cerebral protection devices were
used in all cases. All patients were pretreated with ace-
tylsalicylic acid at a mean dosage of 125 mg/d and
with clopidogrel or ticlopidine at a mean dosage of
75 mg/d or 500 mg/d, respectively, for at least 4 to 5
days prior to admission. All the procedures were
carried out percutaneously via puncture of the
right and/or left femoral artery. Weight-adjusted
(70 U/kg) heparin was administered and repeated as
necessary to maintain an activated clotting time of
225 to 250 seconds throughout the procedure. Based
on the experience with percutaneous coronary angio-
plasty and stenting, the common carotid artery
(CCA) was selectively engaged directly by using an
appropriate 8-F guiding catheter.When the use of a pri-
mary guide catheter was not possible due to the partic-
ular anatomy of the supra-aortic vessels, a stiff
guidewire was placed into the external carotid artery
to position a long sheath or a guiding catheter (coaxial
technique) into the CCA. Atropine (0.5 to 1 mg) was
given intravenously to most patients just before the
post-stenting dilation phase to reduce bradycardia
and hypotension potentially associated with carotid
dilation. Atropine was not administered in patients
with tachycardia and uncontrolled systemic hyper-
tension. All patients underwent an angiographic
657Is CAS the Standard of Care?examination of the culprit carotid lesion in 2 projec-
tions and an angiographic examination of the intracra-
nial circulation in anteroposterior and/or lateral
projections. The same angiographic imaging was per-
formed at the end of the procedure to determine
whether there was any variation in the intracranial
blood flow. Clopidogrel (75 mg/d) or ticlopidine
(500 mg/d) was continued for at least 30 days after
the interventional procedure (hemoglobin and white
blood count were checked 7 to 10 days following the
percutaneous intervention). Mono antiplatelet therapy
(aspirin, clopidogrel, or ticlopidine) was continued
indefinitely.11
CEA Procedure
Out of 1589 CEA procedures the majority (n¼ 1502,
94.5%) were performed using local anesthesia (cervi-
cal block plus local infiltration). The remaining 87
cases received general anesthesia due to reduced com-
pliance to local anesthesia of the patients (n¼ 35) or to
urgent cases (n¼ 62). 1424 (89.6%) CEAs were per-
formed using a standard medial approach and 165
(10.4%) using a retrojugular12 approach to the carotid
bifurcation. In 1253 (78.8%) CEAs a longitudinal arte-
riotomy was used and in 336 (21.2%) an eversion end-
arterectomy was employed. The use of temporary
shunting and patch closure was selectively done.
Dacron patch angioplasty was used in 82.1% cases, in-
cluding in 87.5% of the female patients. Pre-procedure
medical treatment was to stop anti-platelet therapy
5-6 days before the procedure and to continue low-
molecular-weight heparin, 4000 IU SC a day until
the day of procedure. Weight-adjusted (70 U/kg) hep-
arin was administered during the procedure and
repeated as necessary to maintain an activated clot-
ting time of 225 to 250 seconds throughout the pro-
cedure. The day after the procedure, we started
mono anti-platelet therapy (aspirin, clopidogrel or
ticlopidine), which continued indefinitely.
Table 2. Baseline ultrasound lesion characteristics between treat-
ment arms. CAS, carotid artery stenting; CEA, endarterectomy;
PSV, Peak systolic velocity; EDV, End Diastolic Velocity
CAS¼ 1035 CEA¼ 1589
PSV 297 113 cm/sec 301 126 cm/sec
EDV 123 79 cm/sec 137 64 cm/sec
Lesion characteristics No. % No. %
TYPE I 237 22.89 709 44.65 p< 0.01
TYPE II 252 24.37 359 22.62 p¼ 0.43
TYPE III 237 22.90 308 19.38 p¼ 0.08
TYPE IV 309 29.84 213 13.35 p< 0.01Follow-Up
Echo-duplex and neurological examinations of all
patients were carried out at 1, 3, 6 and 12 months after
the procedure and then yearly. Patients were in-
structed to inform the vascular surgeon when any
new symptoms occurred after hospital discharge.
Statistical Analysis
All results were analyzed using SPSS statistical soft-
ware (SPSS, Chicago, IL). All values were expressed
as mean SD. The Fisher exact test was used to com-
pare the rates between the two study groups (CEA vs.
CAS) for categorical variables, and all probability
values were two-tailed, with a value of p< 0.05 con-
sidered as statistically significant. The Pearson c2
test was used to evaluate the relationship between
the categorical variables and the two study groups.
Logistic regression was used to compare the stroke
and death rate between the two study groups at 30
days, 1 year and 3 years. To evaluate the fate of the
CAS and CEA patients, Kaplan-Meier survival analy-
ses were generated for overall survival and freedom
from neurological events.
Results
CAS was successfully performed in 1027/1035 cases
(99.2%). The eight failed attempts were due to com-
plex vessel access and underwent immediate intra-
operative conversion to CEA. In these 8 patients we
did not have any neurological complications at 30
days. The mean intervention time was 24 11 min-
utes (77 26 minutes for CEA).
The neurological and cardiac complications are
described in Table 3. No intra-procedural death
occurred.
Thirty-Day Outcome
We reported 2 deaths in the CAS group (one
procedure-related death -congestive heart failure-
and one non-procedure-related death at postoperative
day 25 -acute pulmonary edema in dilative cardiomy-
opathy), 3 fatal strokes (2 intracranial hemorrhages, 1
severe cerebral embolization at postoperative day 1),
3 major strokes (1 acute in-stent thrombosis) and 8
minor strokes. All patients who experienced a major
complication were neurologically symptomatic before
CAS. In asymptomatic patients there were a number
of transient ischemic attacks (13/596; 2.18%), with
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only 2 MIs.
In the subgroup of urgent CAS procedures, we ob-
served a death/stroke rate of 6.06% at 30 days (no
deaths, 2 minor strokes in patients already suffering
from severe neurologic deficit before the procedure,
and 1 TIA).
We observed 6 fatal strokes in the CEA group (5
intracranial hemorrhages, 1 massive ischemic lesion),
8 major strokes and 13 minor strokes. 65.7% of
Table 3. Overall neurological complications. CAS, carotid artery
stenting; CEA, endarterectomy; TIA, Transient Ischemic Attack
Clinical outcome
CAS CEA
Events during procedure No. % No. %
Death (any cause) 0 0.00 0 0.00
Major stroke 0 0.00 2 0.12
Minor stroke 2 0.19 4 0.25
TIA 6 0.58 13 0.82
Myocardial Infarction 0 0.00 0 0.00
Cranial neuropathy e e 33 2.08
Postoperative Events,
at discharge
No. % No. %
Death (any cause)
procedure related
3 0.29 7 0.44
Death (any causes)
not procedure related
0 0.00 2 0.12
Major stroke 3 0.29 5 0.32
Minor stroke 5 0.48 9 0.56
TIA 7 0.68 4 0.25
Myocardial Infarction 2 0.19 7 0.44
All strokes and death at discharge 13 1.26 29 1.82 p¼ 0.34
Events between
discharge and 30 days
No. % No. %
Death (any cause)
procedure related
1 0.1 3 0.12
Death (any causes)
not procedure related
1 0.1 0 0.00
Major stroke 0 0.00 1 0.06
Minor stroke 1 0.1 0 0.00
TIA 3 0.29 0 0.00
All TIAs at 30 days 16 1.54 17 1.07 p¼ 0.29
Myocardial Infarction at 30 days 2 0.19 7 0.44 p¼ 0.5
All stroke and death at 30 days 16 1.54 33 2.07 p¼ 0.37
Events between 30 days
and 1 year
No. % No. %
Death (any cause)
procedure related
1 0.12 3 0.23
Death (any causes)
not procedure related
4 0.48 5 0.39
Major stroke 1 0.12 2 0.15
Minor stroke 2 0.23 3 0.23
TIA 5 0.56 7 0.54
All TIAs at 1 year 21 2.5 14 1.08 p¼ 0.01
All stroke and death at 1 year 24 2.86 46 3.55 p¼ 0.45
Events between 1 and 3 years No. % No. %
Death any cause 5 1.06 8 0.82
Major & Minor stroke 6 1.27 14 1.43
TIA 11 2.33 27 2.76
All TIAs at 3 years 32 6.79 41 4.19 p¼ 0.05
All stroke and death at 3 years 35 7.43 68 6.95 p¼ 0.74
Eur J Vasc Endovasc Surg Vol 34, December 2007patients who had experienced a complication were
neurologically symptomatic before CAS. Moreover
we reported 4 procedure-related deaths (3 MIs at
postoperative days 1, 3 and 7) and 2 non-procedure-
related deaths at postoperative days 17 and 29 (road
accident, re-activation of viral hepatitis). MI occurred
in 7 patients.
In the subgroup of urgent CEA procedures, we
observed a death/stroke rate of 6.45% at 30 days
(1 death, 1 major stroke and 2 minor strokes).
The overall death and stroke rate at 30 days was
1.54% in the CAS group and 2.07% in the CEA group
( p¼ 0.37).
Later Outcomes
Between the 30-day and 1 year periods (patients with
complete follow-ups at 1 year were 735/937, 78.4%,
for the CAS group and 1276/1368, 93.3%, for the
CEA group), the incidence of new strokes was 0.95%
and 1.00% respectively for CAS and CEA (p¼>1).
At 1 year follow-up we observed 5 deaths (1 hemor-
rhagic stroke, 1 MI, 2 congestive heart failure, 1 acute
lymphoma) in the CAS group and 8 deaths in the
CEA group (3 hemorrhagic strokes, 3 MIs, 1 pneumo-
nia, 1 gastric cancer), 3 major strokes (1 in the CAS
group, 2 in the CEA group), 5 minor strokes (2 in
the CAS group, 3 in the CEA group). The overall
death and stroke rate at 1 year was 2.86% in the
CAS group and 3.55% in the CEA group (p¼ 0.45).
The overall death and stroke rate at 3 years
(patients with complete follow-up at 3 years were
442/937, 47.1%, for the CAS group and 983/1368,
71.8%, for the CEA group) was 7.43% in the CAS
group and 6.95% in the CEA group (p¼ 0.74).
The cumulative freedom from neurological events
and cumulative survival analysis are shown in
Figs. 1 and 2.
In-stent restenosis after CAS, at 1 year, occurred in
18 patients (2.45%) while restenosis after CEA
occurred in 26 patients (2.04%) (p¼ 0.63).
Discussion
The critical safety objective of carotid intervention is
the avoidance of stroke, in particular, disabling stroke.
On the basis of several trials,3,4,13,14 CEA is generally
considered the standard therapy for severe carotid ar-
tery disease. Recent trials have concentrated on inves-
tigating CAS, however there is no general agreement
whether it should be accepted as an alternative ther-
apy to CEA. This uncertainty is in part due to the
659Is CAS the Standard of Care?Fig. 1. Cumulative freedom from neurological events. CAS, carotid artery stenting; CEA, endarterectomy; TIA, Transient
Ischemic Attack.lack of large randomized trials comparing endarterec-
tomy to stenting and the fact that current trials have
failed to establish a clear consensus.6,15e23 The recent
EVA 3-S22 trial found CEA to be superior to CAS.
However, many of these trials have been heavily
criticised 24e27 making interpretation of their findings
difficult.
We are aware of 5 ongoing randomized trials.28e32
The results of these trials will provide a more robust
level of evidence regarding the risks and benefits of
CAS. The experiences of the CAS Registries combined
with those of single centers are currently supplyingmore data about long term results.33e35 Our experience
with CAS started six years ago. Initially we carefully
selected patients and focused endovascular treatment
on patients with anatomically complex situations (hostile
necks, deleterious neck surgery with tracheostomy,
secondary interventions after endarterectomy, cervical
radiotherapy, carotid stenosis after radiotherapy, large
and short neckwith high bifurcation, carotid bypass ste-
nosis) or with poor clinical conditions where surgery offers
worse results (contralateral occlusions, deficient Circle
of Willis, severe coronary diseases, neurological deficit,
heart failure or pending coronary revascularization,Fig. 2. Cumulative survival analysis. CAS, carotid artery stenting; CEA, endarterectomy.
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660 C. Setacci et al.low life expectancy due to tumors, or old age) [High-risk
patients]. Year after year of experience with CAS
optimized our learning curve and the results obtained
supported our conviction of offering CAS as the first
choice to patients with severe carotid stenosis as shown
in Table 4.
At the moment CAS is relatively contraindicated in
our center to the following categories of patients: pa-
tients with floating thrombus in the internal carotid
or common carotid arteries36 (some authors described
a different approach to this open question37) or very
young patients ( 50 years) if they are at standard
risk for CEA (ASA 2. Score of the American Society
of Anesthesiologists).
During these six years we observed a drastic drop
in the number of CEA procedures and on the contrary
a rapid growth in the number of CAS procedures as
shown in Fig. 3. The very infrequent periprocedural
strokes seen in this review were presumably related
to small emboli released during the manipulation of
the arch, previous to catheter access into the common
carotid artery, before embolic filter protection was in
place and at the post-dilatation of the stent. Despite
the fact that the immediate periprocedural and in-
hospital results are encouraging, we are aware thatembolic protection devices (in all their forms) allowed
operators to protect the procedure.33,38,39
Long-term stroke prevention in our treated patients
is the hallmark of successful carotid intervention. The
1 and 3 year rates of ipsilateral stroke for CAS in this
review are 2.86 and 7.43%, respectively, similar to
those of CEA (3.55% and 6.95%, p value not
significant).
We believe that on the basis of the current evidence,
CAS with cerebral protection, in the hands of experi-
encedoperators, can be consideredequal if not superior
to CEA in high-risk patients. On the basis of our results
we demonstrate that if specific devices applied to spe-
cific lesions and/or anatomies are used (‘‘tailored’’
CAS strategy),40 the endovascular procedure can be
successful with a very low complications (Fig. 4). The
‘‘tailored’’ CAS strategy bases its rationale mostly on
the complete knowledge of the patient’s clinical status,
vascular anatomy, carotid plaque characteristics and
complexity.We believe that the pathological conditions
have to be matched to the technical features of the ma-
terials at the disposition of the operator. Another im-
portant factor is that the best medical treatment has
also dramatically improved compared to 20e25 years
ago (the NASCET ‘‘era’’). There are now many moreTable 4. Our management strategy for patients with carotid stenosis. MR, magnetic resonance; CTcomputed tomography; ICA, internal
carotid artery; CCA, common carotid artery; CAS, carotid artery stenting; CEA, carotid endarterectomy; BMT, best medical treatment
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661Is CAS the Standard of Care?medication to treat hypertension, dyslipidemia, coro-
nary heart disease and diabetes. For example, there is
convincing evidence that clopidogrel, a newgeneration
of anti-platelet anti-aggregation drugs used widely for
CAS in addition to aspirin, reduces the risk of myocar-
dial infarction.41,42
We strongly believe as well that the treatment of se-
vere carotid stenosis must be successfully managed
by skilled operators in high-volume centers. These
must be performed by centers of vascular surgery, be-
cause the vascular surgeon is the operator most famil-
iar with the pathology, the anatomy, hemodynamics
and the correlation between Echo-duplex findings
and lesion characteristics. These, combined with cor-
rect patient and lesion analyses, should indicate the
Fig. 4. Stroke and Death rate at 30 days, from 2000 to 2006
for CAS and CEA. CAS, carotid artery stenting; CEA,
endarterectomy.
Fig. 3. CAS and CEA procedure during the last 6 years.
CAS, carotid artery stenting; CEA, endarterectomy.right intervention for each individual patient (‘‘tai-
lored’’ procedure). A ‘‘tailored’’ procedure is possible
only when the operator is completely familiar with
both procedures.
Conclusions
We present our experience of CAS compared to CEA.
We have developed an approach to use CAS as a first
option, and we indicate CEA only for younger pa-
tients and those with particular hypoechoic lesions
at duplex imaging. In our center, with our experience,
we can now offer both CEA and CAS to the patient
with the same awareness and confidence. For now,
the literature lacks evidence to support our conclu-
sions, and additional trials and registers will be neces-
sary. At this time in Italy there is a simple, clear and
updated evidence-based consensus document drawn
up by an Italian multidisciplinary task force (neurolo-
gists, neuroradiologists, radiologists, cardiologists,
vascular surgeons) for CAS and the prevention and
treatment of carotid artery disease (Carotid Artery
Stenting. First Consensus Document of the ICCS-
SPREAD Joint Committee).43
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